The CALM/AF10 fusion gene is found in various hematological malignancies including acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia and malignant lymphoma. We have previously identified the leukemia stem cell (LSC) in a CALM/AF10-driven murine bone marrow transplant AML model as B220+ lymphoid cells with B-cell characteristics. To identify the target cell for leukemic transformation or 'cell of origin of leukemia' (COL) in non-disturbed steady-state hematopoiesis, we inserted the CALM/AF10 fusion gene preceded by a loxP-flanked transcriptional stop cassette into the Rosa26 locus. Vav-Cre-induced panhematopoietic expression of the CALM/AF10 fusion gene led to acute leukemia with a median latency of 12 months. Mice expressing CALM/AF10 in the B-lymphoid compartment using Mb1-Cre or CD19-Cre inducer lines did not develop leukemia. Leukemias had a predominantly myeloid phenotype but showed coexpression of the B-cell marker B220, and had clonal B-cell receptor rearrangements. Using whole-exome sequencing, we identified an average of two to three additional mutations per leukemia, including activating mutations in known oncogenes such as FLT3 and PTPN11. Our results show that the COL for CALM/AF10 leukemia is a stem or early progenitor cell and not a cell of B-cell lineage with a phenotype similar to that of the LSC in CALM/AF10+ leukemia.
INTRODUCTION
The t(10;11)(p13;q14) is a rare but recurring chromosomal translocation leading to an in-frame fusion of the AF10 (ALL1 Fused gene from chromosome 10, MLLT10) gene on chromosome 10 and the CALM (Clathrin Assembly Lymphoid Myeloid, PICALM) gene on chromosome 11. 1 The CALM/AF10 (C/A) fusion was initially cloned from the monocytic cell line U937, which was derived from a patient with histiocytic lymphoma. 1 The C/A fusion is found in various hematological malignancies including acute myeloid leukemia (AML), acute lymphoblastic leukemia and malignant lymphoma. [2] [3] [4] [5] [6] [7] [8] [9] It is predominantly encountered in young patients and is associated with a poor prognosis. 2, 6, [9] [10] [11] In T-cell acute lymphoblastic leukemia with T-cell receptor γδ rearrangement, the C/A fusion is the most frequent genetic abnormality with a prevalence of up to 30%. 12 CALM encodes a ubiquitously expressed protein involved in clathrin-mediated endocytosis and vesicular trafficking between the trans-golgi network and endosomes. 13 A nonsense point mutation in the murine Calm gene leads to hematopoietic abnormalities and a shortened lifespan in fit1 mutant mice. 14 AF10 was initially identified as a fusion partner of the mixed lineage leukemia (MLL1) gene. 15 AF10 has an N-terminal plant homeodomain and a C-terminal octapeptide motif-leucine zipper domain. 16, 17 The C-terminal octapeptide motif-leucine zipper domain is essential for AF10-mediated transformation 18 and also for mediating its interactions with the histone H3 lysine 79 methyltransferase hDOT1L 9 and the lymphoid regulator Ikaros (IKZF1). 20 Panhematopoietic transgenic expression of C/A from a Vav promoter resulted in AML with a long latency of 12 months and a low penetrance of 40%. 21 Introducing additional genetic lesions in these mice by retroviral integration accelerated disease induction and increased penetrance. 22 However, in a murine bone marrow transplantation (BMT) model, the retroviral expression of the C/A fusion protein led to an aggressive AML within 15 weeks in all mice. 23 The leukemia cells had a predominantly myeloid phenotype but were also positive for clonal B-cell receptor rearrangements. In this C/A BMT model, we were able to identify the leukemia stem cell (LSC) as residing in a small sub-population of leukemia cells that were myeloid marker negative but positive for the B-cell marker B220. Importantly, human C/A+ AML patient samples expressed CD45RA, the human homolog of murine B220, and showed immunoglobulin H (IgH) and T-cell receptor rearrangement.
cassette into the genome is random, resulting in variability of transgene expression. In our C/A BMT, recipient mice have their BM ablated before transplantation and therefore hematopoiesis is severely perturbed with the retrovirally modified donor cells going through a phase of rapid proliferation after the transplant.
To determine the target cell or 'cell of origin of leukemia' (COL) for C/A-mediated transformation in the setting of undisturbed, steady-state hematopoiesis, we generated a C/A knock-in mouse model (Rosa26 loxP-stop-loxP-CALM/AF10; R26LSLCA) with Cre-mediated expression of the C/A fusion from the Rosa26 locus. Expression of C/A in the entire hematopoietic compartment after Vav-Cre-mediated recombination caused AML with a median latency of 1 year and 100% penetrance. Most leukemias had clonal B-cell receptor rearrangments, and 40% of the leukemias also expressed the B-cell marker B220. Interestingly, the C/A fusion did not induce leukemia when it was expressed in cells of the B-cell lineage with a similar phenotype to the C/A LSC found in the BMT model using Mb1-Cre-or CD19-Cre-mediated recombination. Leukemic cells from Vav-Cre × R26LSLCA mice showed overexpression of Hoxa cluster genes and the Hox cofactor Meis1 and had a gene expression profile that resembled human C/A+ leukemias. Whole-exome sequencing (WES) revealed additional somatic mutations, some of them in known oncogenes such as FLT3 and PTPN11. In summary, our results show that the COL for C/A in unperturbed hematopoiesis is a hematopoietic stem cell (HSC) requiring additional genetic hits and that C/A is incapable of transforming cells of the B-cell lineage even though the LSC in established C/A leukemia has B-cell lineage characteristics.
MATERIALS AND METHODS

Generation of the R26SLSCA knock-in mouse line
The C/A fusion cDNA was cloned into the pRosa26PA vector to generate the targeting construct R26LSLCA (Supplementary Figure S1A) , which was electroporated into 129X1/SvJ mouse embryonic stem cells. Recombinant embryonic stem cells were injected into C57BL/6 blastocysts that were transferred into foster mice to generate chimeric animals. A detailed description of the process is provided in Supplementary Methods.
Cre-induced expression of C/A R26LSLCA mice were mated with Vav-Cre, 24 Mb1-Cre (mb1Cre) 25 or CD19-Cre 26 mice (all C57BL/6 background) to achieve panhematopoietic or B-cell-specific expression of the C/A fusion gene. Mice were bred and maintained under specific pathogen-free conditions. All experiments were performed in compliance with the German Animal Welfare Act and were approved by the Government of Upper Bavaria, Germany.
Analysis of leukemic mice
Mice expressing the C/A fusion were closely monitored and killed for postmortem analysis when moribund. Peripheral blood (PB), bone marrow (BM) and spleen (Spl) cells were analyzed by flow cytometry (FACS) using B220, CD19, CD24, CD4, CD43, CD8, cKit, Gr1, Mac1, Sca1 and Terr119 (BD Biosciences, Heidelberg, Germany), and F4/80 (Santa Cruz, Heidelberg, Germany) antibodies using a FACSCalibur (BD Biosciences). Results were analyzed with CELLQuest (BD Biosciences).
PB smears, BM and Spl cytospins were assessed microscopically after Giemsa-May-Grünwald staining (Merck, Darmstadt, Germany). Paraformaldehyde fixed internal organs were prepared for standard hematoxylin and eosin staining, naphthol-AS-D-chloroacetate esterase (ASDCL) staining and for immunohistochemistry using antibodies against myeloperoxidase, B220, CD3 and terminal desoxynucleotide transferase. The Bethesda proposals for the evaluation of leukemic tissues were followed. 27, 28 Images were taken using an Axioskop 40 microscope (Carl Zeiss, Jena, Germany) and processed using Adobe Photoshop CS3 (Adobe Systems GmbH, Munich, Germany).
Gene expression profiling and microarray analyses BM and B cells were sorted on a BD FACSVantage SE System (BD Bioscience) using Gr1, Mac1 and B220 antibodies and total RNA and cDNA were prepared using TRIzol reagent (Life Technologies, Darmstadt, Germany) and Ambion WT Expression Kit (Life Technologies) and hybridized to Mouse Gene 1.0 ST transcript cluster arrays (Affymetrix, Santa Clara, CA, USA). Data normalization was performed using the Robust Multichip Average method as described. 29 The Linear Models for Microarray Data (LIMMA) package was used to compute differentially regulated probe sets. The R 2.12.2 and 3.0.1 software and routines from the Bioconductor biostatistics software repository were used for all statistical analyses. 30 Heatmaps were generated with the heatmap.2 function (r-package gplots) using the hclust function for hierarchical clustering. 31 All the expression data are publicly available on the Gene Expression Omnibus website (GSE58853).
Quantitative TaqMan real-time PCR Expression levels of the C/A fusion transcript, and Hoxa5, Hoxa7, Hoxa9, Hoxa10, HoxB4, Meis1 and Bmi1 genes were determined by TaqMan realtime PCR (for primers and probes, see Supplementary Table S1 ). cDNA was prepared using the Thermoscript RT-PCR System (Life Technologies). Expression levels of the murine β-actin and 18srRNA genes were used as internal controls (Life Technologies). Expression levels were calculated using the ΔC T method.
Analysis of DJ and VDJ BCR rearrangments
Analysis of the DJ and VDJ rearrangements of the murine B-cell receptor genes was performed using PCR-based assay on genomic DNA of leukemic BM as described before. 23 Whole-exome sequencing Genomic DNA was prepared from unsorted BM cells of leukemic mice using the AllPrep DNA/RNA Kit (Qiagen, Hilden, Germany). Tail snip genomic DNA from the same mice was used as the germline control. Genomic DNA (0.5-1 μg) was fragmented to an average size of 250 bp using a Bioruptor sonicator (Diagenode, Seraing, Belgium). Paired-end sequencing library preparation and exon capturing were performed using the SureSelectXT Mouse All Exon Kit (Agilent, Waldbronn, Germany). Exome libraries were sequenced with 76-bp paired-end reads on a Genome Analyzer IIx (Illumina, San Diego, CA, USA). Sequences were mapped to the NCBI Mouse mm9 reference genome and somatic mutations were called by comparing leukemic samples to all germline control samples. Variants annotated as polymorphisms in the dbSNP v128 database were removed before further analysis. Nonsynonymous somatic variants detected in leukemic samples were verified by Sanger sequencing using a 3500xL Genetic Analyzer (Life Technologies, Darmstadt, Germany)).
Statistical analysis
PB counts and percentages of immune cell subsets in PB, BM, and Spl were compared between mice using two-tailed unpaired Student's t-tests.
RESULTS
Vav-Cre-mediated expression of the C/A fusion gene causes leukemia To examine the requirements for C/A-induced leukemia in unperturbed hematopoiesis, we generated the R26LSLCA mouse model (Supplementary Figure S1) , allowing the tissue-specific expression of the C/A fusion from the Rosa26 promoter following Cre-mediated excision of a loxP site-flanked transcriptional stop cassette (Supplementary Figure S2) . To achieve panhematopoietic expression of the C/A fusion, R26LSLCA mice were crossed with Vav-Cre mice to give rise to heterozygous CA+/Vav-Cre+ progeny. To achieve B-cell-specific expression of C/A, R26LSLCA mice were crossed with Mb1-Cre and CD19-Cre mice, which resulted in CA +/Mb1-Cre+ and CA+/CD19-Cre+ offspring, respectively.
All (Figure 3 ). Mac1+ cells comprised a median of 70% (range 45-92%), 29% (range 7-71%) and 45% (range 26-64%) of total PB, BM or Spl, respectively. This is a statistically significant increase over wild-type mice (P o 0.0001) (Figure 3b ).
The percentage of CD3 + T cells was reduced in all organs of leukemic CA+/Vav-Cre+ mice.
In 6 out of 15 (40%) leukemic CA+/Vav-Cre+ mice, a median of 37% (range 35-47%), 32% (range 20-51%) and 43% (range 40-49%) cells in the PB, BM and Spl, respectively, costained for Mac1 and the B-cell marker B220 (Figures 2b and 3) . This biphenotypic population of cells was absent in the other nine leukemic mice. We called the former six leukemias 'biphenotypic' and the latter nine leukemias 'myeloid'. We did not detect pronounced changes in the expression of other surface markers such as cKit, CD24, F4/80 and CD19 between the two groups of leukemia; however, Gr1 and cKit were low in the biphenotypic group (Supplementary Figure S3) .
The CA+/Mb1-Cre+ and the CA+/CD19-Cre+ mice did not show significant changes in their hematopoietic organs (Supplementary Figure S4 ) even though their B cells expressed C/A at comparable levels to the leukemic BM cells from CA+/Vav-Cre+ mice (Supplementary Figure S5) .
Both biphenotypic and myeloid CA leukemias have clonal B-cell receptor DJ rearrangements When we performed PCR assays to detect B-cell receptor (BCR) DJ rearrangements in the genomic DNA of four myeloid and four biphenotypic leukemias, clonal DJ rearrangements were Figure S7 ) yielded only 14 significantly deregulated probe sets (P-value o0.001). Importantly, these included the upregulation of Hoxa3, Hoxa5, Hoxa6 and Meis1 (Supplementary Table S4 ).
Comparing GEPs of CALM/AF10-expressing B cells from nonleukemic CA+/Mb1-Cre+ mice to that of wild-type B cells (comparison 5 in Supplementary Figure S7 ), a total of 32 probe sets was found significantly deregulated (P-value o0.005; P-value is less stringent). Eight annotated probe sets were upregulated and six were downregulated (Supplementary Table S5 ). Again Hoxa3, Hoxa5 and Hoxa6 and Meis1 were found upregulated in the C/A-expressing non-leukemic B cells.
The high expression levels of Hoxa5, Hoxa7, Hoxa9, Hoxa10 and Meis1 in leukemic BM and Spl of CA+/Vav-Cre+ mice were confirmed by quantitative reverse transcription-PCR (Figure 5b) . In contrast to the microarray, we did not see significantly higher expression of any Hoxa gene or Meis1 in B cells from CA+/Mb1-Cre+ mice (Figure 5b ) using real-time reverse transcription-PCR, probably due to a very moderate increase in expression.
Myeloid and biphenotypic C/A-driven leukemias show distinct GEPs To gain further insight into the two phenotypically different CA leukemias, we sorted Gr1+/Mac1+ BM cells from myeloid leukemia (n = 4) and B220+/Mac1+BM cells from biphenotypic Table S6 ). We detected 343 differentially regulated probe sets (P-value o 0.001), of which 251 had a gene annotation.
Differentially regulated genes reflected the immunophenotypic differences between the two groups. Interestingly, in biphenotypic leukemic, we detected upregulation of T-lymphoid-specific genes such as Dpp4 (CD26), Cd7 and Btla. . The numbers refer to the probe sets for which a gene annotation was available. Twenty-five genes were found deregulated in both comparisons, including six Hoxa cluster genes and the Hox cofactor Meis1. (Right panel) Heatmap of these 25 deregulated genes in preleukemic and leukemic BM as compared with wild-type BM. (b) Quantitative reverse transcription-PCR of Hoxa cluster genes, Meis1, and Bmi1 transcript levels. Expression of Hoxb4 was assayed as a control outside the Hoxa cluster. Expression was normalized to β-actin and is presented as ΔC T . *P ⩽ 0.02; **P ⩽ 0.002. Expression levels were compared between leukemic CA+/Vav-Cre+ BM (n = 4) and wild-type BM (n = 3), leukemic CA+/Vav-Cre+ Spl (n = 4) and wild-type Spl (n = 3) and CA+/Mb1-Cre+ B cells (n = 3) and wild-type B cells (n = 4). Note that Hoxa7, Hoxa9 and Hoxa10 transcripts were detected in leukemic Spl but not in wild-type Spl. Hoxa7, Hoxa9 and Hoxa10 transcripts were not detected in either CA+/Mb1-Cre+ B cells or wild-type B cells.
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WES reveals additional somatic mutations in C/A-driven murine leukemia, which can also be found in human C/A+ leukemia The long latency to leukemia onset in CA+/Vav-Cre+ mice together with the apparent necessity of the C/A fusion to be expressed in very early stages of hematopoiesis prompted us to search for additional mutations in the CA leukemias. To identify leukemia-specific somatic variants, we performed WES and compared the exomes of seven CA+/Vav-Cre+ leukemic samples with their corresponding germline controls. We identified between one and six somatic point mutations and indels per sample in the five exomes with the highest coverage and blast counts (Table 1 and Supplementary Figure S11 ). As expected, we observed a strong correlation between the number of mutations identified and the sequence coverage and blast percentages (Supplementary Tables S7 and S8 and Supplementary Figure S12) . Interestingly, we found two distinct point mutations in the same gene, 4930595M18Rik, in leukemic exomes Leu51 and Leu95. In addition, we found mutations in two known leukemia driver genes: in Ptpn11 (exon 13) and in codon 838 (D838) in the tyrosine kinase domain of the Flt3 gene. Interestingly, PTPN11 mutations were also found in two of seven CALM/AF10+ leukemia patients and in the CALM/AF10+ cell line U937, which were subjected to gene panel sequencing (10 genes) (Supplementary Figure S13 and Supplementary Table S9) . DISCUSSION AML clonally originates from a single transformed cell 32 -often called the target of transformation or COL. In the established leukemia, only a small population of tumor cells, often referred to as the 'leukemia-propagating cells', 'leukemia-initiating cells' or LSCs are clonogenic in culture 33 and able to propagate and maintain the disease in vivo. 34 The target of transformation can either be HSCs or committed progenitors, depending on the oncogene and the assay system used. 35, 36 MLL-AF9, for example, can confer self-renewal properties to common myeloid progenitors and granulocyte-macrophage progenitors, 35 BCR/ABL can only transform long term-HSCs 37 and MN1 can transform HSCs and common myeloid progenitors but not granulocyte-macrophage progenitors. 38 To study the target of transformation of the CALM/AF10 fusion gene, we chose a knockin approach, which does not suffer from some of the shortcomings of the BMT leukemia models related to retroviral insertional mutagenesis, polyclonality and a highly perturbed hematopoietic system after the transplant.
The association of C/A fusion with acute lymphoblastic leukemia as well as AML suggests that an immature hematopoietic cell is the likely target for transformation by C/A. Using a murine BMT model, we have previously shown that in C/A-driven AML, the LSC was characterized by the expression of B220, DJ rearrangements in the B-cell receptor genes and the absence of myeloid markers. 23 In the transgenic model of Caudel et al., 21 the C/A fusion is driven from the Vav promoter. In this model, the leukemic phenotype is similar to the phenotype our previous BMT model 23 and in the CA+/Vav-Cre+ mice in the present study. The leukemias were either myeloid or biphenotypic with the expression of both Mac1 and B220. Our CA+/Vav-Cre+ and the transgenic Vav-C/A 21 models have comparable latencies. However, the Vav-C/A transgenic mice showed a much lower leukemia penetrance (about 50%) compared with our model (100%). This difference might be strain specific or due to the fact that CA+/VavCre+ mice are expressing C/A from the Rosa26 promoter and not from a randomly integrated Vav-C/A transgenic construct.
The coexpression of B220, which is expressed from the pro-Bcell stage onwards, and myeloid markers appears to be common in C/A-induced murine and human leukemia. 21, 23 As C/A-induced biphenotypic leukemic cells do not express the B-cell markers CD79a, IgM or CD19, the aberrant expression of B220 might be a direct effect of C/A-mediated activation of the transcription of B220. In our previous BMT model, the leukemic clones recurrently showed clonal D H -J H rearrangement, suggesting that malignant transformation might have occurred at or after the pro-B-cell stage. 23 However, whether the B-lymphoid phenotype in this model was really due to the transformation of a B-cell progenitor or because the C/A fusion favors the differentiation along the B-lymphoid lineage was not known. To distinguish between these two possibilities, we developed mouse strains that would allow lineage-specific as well as panhematopoietic C/A expression from CALM/AF10 in leukemogenesis S Dutta et al a C/A allele knocked into the Rosa26 locus that can be activated by Cre-mediated excision of a transcriptional stop cassette.
In CA+/Mb1-Cre+ mice, the expression of the C/A fusion begins at the very early pro-B-cell stage with the activity of the CD79a (Igα/Mb1) promoter, and in CA+/CD19-Cre+ mice, the expression of the C/A fusion starts from the pre-B-cell stage. When Hobeika et al. 25 tested the recombination efficiency in Mb1-Cre mice using a Rosa-floxed EYFP reporter mouse line, along with the strong YFP signals in the B cells from the early pro-B-cell stage onward, they reported seeing low levels of YFP+ T cells in the thymus, Spl and lymph nodes. This strongly suggests that Mb1-Cre-mediated recombination can take place in the very early progenitors that are not irreversibly committed to the B-cell fate, probably to some extent in CLPs. In a very recent work, Duque-Afonso et al. 39 have conditionally expressed the E2A-PBX1 fusion protein using Mb1-Cre and CD19-Cre and achieved acute B-lymphoblastic leukemia in 59% and 7% of the mice, respectively. This shows that cells expressing Mb1 and even CD19 are still capable of malignant transformation.
Interestingly, the expression of C/A after either Mb1-Cre-or CD19-Cre-mediated recombination did not result in leukemia development. In contrast, panhematopoietic expression of C/A after Vav-Cre-mediated recombination led to leukemia with a median latency of about 1 year. These results show that C/A is only leukemogenic when expressed in the correct cellular context, most probably in an HSC or an early hematopoietic progenitor. In addition, these results clearly show that early pro-B cells, which are similar in differentiation stage to the LSC of CA leukemias identified in the BMT model, cannot be transformed into leukemic cells. Thus, at least in CA leukemias there is a clear distinction between the target of transformation or COL and the LSC. Further, and almost certain proof that the COL and LSC are distinct in CALM/AF10 leukemias would have to come from extensive serial and limiting dilution BMT experiments in the Vav-Cre/Rosa26-CA leukemia model. The B-cell-like phenotype, including the presence of IgH-DJ rearrangements, of the C/A LSC would then support the hypothesis that the expression of the C/A fusion might drive or favor differentiation along the B-lymphoid lineage ( Figure 6 ).
In line with earlier studies, 21, 40, 41 C/A expression led to increased expression of Hoxa cluster genes and the Hox cofactor Meis1 in BM and Spl samples of leukemic mice. Upregulated expression of these genes in the BM and B cells of young, preleukemic CA+/Vav-Cre+ mice suggests this event to be an early step in C/A-induced transformation. A slightly higher expression of certain Hoxa cluster genes and Meis1 was also observed in the B cells of CA+/Mb1-Cre+ mice. Our results, together with previous observations made by other groups, clearly indicate that the overexpression of AbdB Hox proteins and Meis1 are important factors in C/A-mediated leukemogenesis. However, as overexpression of Hoxa cluster genes and Meis1 was also observed in the preleukemic mice and in mice that would never develop leukemia, it is clear that this overexpression of Hoxa cluster genes and Meis1 is not sufficient for leukemia development.
The long latency of C/A-driven leukemia in our and previous mouse model strongly suggests the requirement for collaborating genetic events. WES identified several somatic mutations in five out of eight leukemic exomes in the setting of unperturbed hematopoiesis without the confounding effects of retroviral insertional mutagenesis. These mutations affected, among others, the Flt3 and the Ptpn11 genes. An association between Flt3 and Ptpn11 (tyrosine-protein phosphatase non-receptor type 11) mutations and murine C/A-driven leukemias has already been reported. 22, 41 We detected a D4H substitution at codon 838 of the murine Flt3 gene. This codon corresponds to D835 in human FLT3 and is the main site of tyrosine kinase domain-activating mutations of FLT3 in human AML. 42 PTPN11 is a negative regulator of the Ras pathway, and mutations in exons 3 and 13 of PTPN11 are found in patients with AML, myelodysplastic syndrome and juvenile myelomonocytic leukemia. 43 We found a missense mutation in exon 13, codon 507, which encodes the catalytic domain of PTPN11, leading to a G4V amino-acid change, a mutation described at the corresponding human codon G503 in juvenile myelomonocytic leukemia. 43 Interestingly, in a small series of seven CALM/AF10-positve acute lymphoblastic leukemia and AML patients as well as the U937 cell line, we found PTPN11 exon 3 mutations in two patient samples and the U937 cell line (3/8 = 38%), indicating that the activation of the RAS pathway might be an important factor in CA-driven leukemias as previously described by others, 22 and that our CA leukemia mouse model not only recapitulates the immunophenotype but also collaborating genetic events of human CA+ leukemias.
Other mutations affected genes encoding for the Rho GTPaseactivating protein Arhgap42, the DNA repair protein Ap5s1, the Golgi-associated protein Grasp65, which regulates spindle dynamics and is important for cell division, 44 and Moesin (Msn), an ERM family protein that crosslinks plasma membranes and actin skeletons, and has a role in cancer progression/ metastasis. 45, 46 We identified one somatic mutation in Ush2a, a gene recently identified as recurrently mutated in splenic marginal zone B-cell lymphoma. 47 Additionally, two different nonsynonymous mutations in 4930595M18Rik in two mice were identified. This gene codes for an RNA recognition motif and a RING-finger domain. It should be noted that there was a strong correlation between the number of somatic mutations detected in the leukemia exomes and the coverage and blast percentage of the individual exome in our WES experiments (Supplementary Figure  S12) . One should bear in mind that WES is not able to detect all leukemia-relevant genomic changes, like copy number changes or translocations. A more complete genomic analysis (WES with a higher coverage, or whole-genome sequencing), with all likelihood, would have uncovered additional genetic alterations and mutations in the two leukemias (Leu74 and Leu31) where no mutations were found using WES. It should also be noted that our very small CALM/AF10 patient cohort was only sequenced using a limited gene panel (10 genes) so that a greater overlap between human and murine collaborating mutations cannot be expected.
In summary, our knock-in mouse model provides evidence that the target cell of transformation or the COL for C/A-mediated transformation is an HSC or a very early multipotent progenitor cell and that this cell is distinct from the C/A LSC. Furthermore, our WES results identified additional mutations that are required to collaborate with C/A to drive full-blown leukemia. Earlier studies from our laboratory have shown C/A to reduce global histone H3 lysine 79 methylation, favoring chromosomal instability and possibly other mutational events. 48 Additionally, studies from our group showed that the expression of C/A leads to the downregulation of DNA repair genes and changes in cell cycle regulation. 49 We propose that the expression of the C/A fusion makes cells more prone to acquire additional mutations. These mutations will have more time to accumulate in HSCs rather than in more committed multipotent progenitor cells as their lifetime is limited. Furthermore, HSCs are more sensitive to mutagenesis than committed progenitors. 50 The development of both myeloid and biphenotypic leukemias in our model is in line with the 'lineage promiscuity' model, which states that leukemias arising from HSCs can still differentiate into the different lineages, 51, 52 and further strengthens our assumption that such early cells are the target of transformation in C/A-induced leukemia.
